循环肿瘤DNA作为肌层浸润性膀胱癌围手术期治疗预测与预后生物标志物的系统综述
本系统综述检索223条记录后纳入6项前瞻性研究,评估循环肿瘤DNA(ctDNA)在肌层浸润性膀胱癌围手术期治疗中的预后与预测价值。综述确认ctDNA在根治性膀胱切除术后具有预后作用,并显示在新辅助化疗和术前免疫治疗中具有潜在预测获益。
要点
- ctDNA是根治性膀胱切除术后肌层浸润性膀胱癌的预后因素,并可能用于监测复发。
- ctDNA状态变化可早于影像学进展,中位时间差为101至932天。
- 在辅助免疫治疗中,ctDNA可能筛选出最获益的患者。
核心结论
- ctDNA是根治性膀胱切除术后肌层浸润性膀胱癌的预后因素,并可能用于监测复发。
- 在辅助免疫治疗背景下,ctDNA可能筛选出最受益于该策略的患者。
研究设计与样本
- 系统综述,遵循PRISMA声明检索PubMed、MEDLINE和Embase数据库。
- 检索获得223条记录,基于预设纳入标准最终纳入6篇论文。
- 纳入研究为前瞻性研究,评估肌层浸润性膀胱癌(T2-T4a、任何N、M0)接受根治性膀胱切除术的新辅助和/或辅助化疗和/或免疫治疗。
主要发现
- ctDNA用于监测复发,ctDNA状态变化可早于影像学进展,中位时间差为101至932天。
- 3期Imvigor010试验亚组分析显示,仅ctDNA阳性且接受阿替利珠单抗治疗的患者无病生存期(DFS)改善(风险比[HR]=3.36,95%置信区间[CI]:2.44-4.62)。
- 辅助阿替利珠单抗治疗两个周期后ctDNA清除与结局改善相关(DFS HR=0.26,95%CI:0.12-0.56,p=0.0014;总生存期HR=0.14,95%CI:0.03-0.59)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Predictive and prognostic biomarkers in the perioperative treatment of muscle-invasive bladder cancer (MIBC) are an unmet need. Circulating tumor DNA (ctDNA) holds promise as a biomarker in this setting. OBJECTIVE: To review the evidence of ctDNA as a prognostic and predictive biomarker in the perioperative treatment of MIBC. EVIDENCE ACQUISITION: We systematically reviewed the literature using PubMed, MEDLINE, and Embase databases according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. We included prospective studies investigating neoadjuvant and/or adjuvant chemotherapy and/or immunotherapy for MIBC (T2-T4a, any N, and M0) treated with radical cystectomy. We reported ctDNA results to monitor and/or predict disease status, relapse, and progression. The research retrieved 223 records. Six papers were considered for this review based on prespecified inclusion criteria. EVIDENCE SYNTHESIS: Our review confirms the prognostic role of ctDNA after cystectomy and shows a potential predictive benefit in using neoadjuvant chemotherapy and preoperative immunotherapy. Circulating tumor DNA was used to monitor recurrence, and changes in ctDNA status anticipated radiological progression with a median difference of time from 101 to 932 d. A subgroup analysis of the phase 3 Imvigor010 trial showed that only ctDNA-positive patients treated with atezolizumab had an improvement in disease-free survival (DFS; hazard ratio [HR] = 3.36, 95% confidence interval [CI]: 2.44-4.62). Clearance of ctDNA after two cycles of adjuvant atezolizumab was associated with improved outcomes (DFS HR = 0.26, 95% CI: 0.12-0.56, p = 0.0014; overall survival HR = 0.14, 95% CI: 0.03-0.59). CONCLUSIONS: Circulating tumor DNA is a prognostic factor after cystectomy and may be used to monitor recurrence. In the adjuvant immunotherapy setting, ctDNA might select patients who benefit the most from this strategy. PATIENT SUMMARY: In the perioperative treatment of muscle-invasive bladder cancer, circulating tumor DNA (ctDNA) positivity correlates with the outcomes after cystectomy and might select patients who may benefit from neoadjuvant chemotherapy and/or immunotherapy. Changes in ctDNA status anticipated radiological progression.
引用
- Crupi E, de Padua TC, Marandino L, et al. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol Oncol. 2023. PMID: 37330413. doi:10.1016/j.euo.2023.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。